Selected Antimicrobial Activity of Topical Ophthalmic Anesthetics

局部眼科麻醉剂的选择性抗菌活性

阅读:1

Abstract

PURPOSE: Endophthalmitis is a rare complication of intravitreal injection (IVI). It is recommended that povidone-iodine be the last agent applied before IVI. Patients have reported povidone-iodine application to be the most bothersome part of IVIs. Topical anesthetics have been demonstrated to have antibacterial effects. This study compared the minimum inhibitory concentration (MIC) of topical anesthetic eye drops (proparacaine 0.5%, tetracaine 0.5%, lidocaine 2.0%) and the antiseptic, 5.0% povidone-iodine, against two organisms causing endophthalmitis after IVI. METHODS: Minimum inhibitory concentration values of topical anesthetics, povidone-iodine, preservative benzalkonium chloride (0.01%), and saline control were determined using five isolates of each Staphylococcus epidermidis and viridans group Streptococcus species (VGS). A broth microdilution technique was used with serial dilutions. RESULTS: Lidocaine (8.53 × 10(-5)mol/mL) had MICs of 4.27 to 8.53 × 10(-5) mol/mL, and tetracaine (1.89 × 10(-5) mol/mL) had MICs of 9.45 × 10(-6) mol/mL for all isolates. Proparacaine (1.7 × 10(-5) mol/mL) had MICs of 1.32 to 5.3 × 10(-7) and 4.25 × 10(-6) mol/mL for S. epidermidis and VGS, respectively). Benzalkonium chloride (3.52 × 10(-7) mol/mL) had MICs of 1.86 × 10(-9) to 1.1 × 10(-8) and 4.40 × 10(-8) mol/mL for S. epidermidis and VGS, respectively. Povidone-iodine (1.37 × 10(-4) mol/mL) had MICs of 2.14 to 4.28 × 10(-6) and 8.56 × 10(-6) mol/mL for S. epidermidis and VGS, respectively. CONCLUSION: Proparacaine was the anesthetic with the lowest MICs, lower than that of povidone-iodine. Benzalkonium chloride had lower MICs than proparacaine. All tested anesthetics and povidone-iodine inhibited growth of S. epidermidis and VGS at commercially available concentrations. TRANSLATIONAL RELEVANCE: For certain patients, it could be possible to use topical anesthetic after povidone-iodine for comfort without inhibiting and perhaps contributing additional antimicrobial benefit.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。